Director/PDMR Shareholding

 

TIDMGWP 
 
RNS Number : 5686P 
GW Pharmaceuticals PLC 
19 July 2010 
 

 
 
 
 
         GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company") 
 
 
NOTIFICATION OF INTERESTS OF DIRECTORS 
Porton Down, UK, 19 July 2010: GW Pharmaceuticals (AIM: GWP) hereby provides 
notification that the Company has today granted the following awards to 
Directors over the Company's ordinary shares ("Shares") in the form of 
nominal-cost options ("Awards") under the GW Pharmaceuticals plc Long-Term 
Incentive Plan: 
 
+-------------------+-------------------+-------------------+ 
|                   |                   |                   | 
| Name              | Number of Shares  | Total number of   | 
|                   | under Award       | Shares over which | 
|                   |                   | options  / awards | 
|                   |                   | held              | 
+-------------------+-------------------+-------------------+ 
| Dr Geoffrey Guy   | 259,836           | 2,049,750         | 
+-------------------+-------------------+-------------------+ 
| Justin Gover      | 213,666           | 2,446,135         | 
+-------------------+-------------------+-------------------+ 
| David Kirk        | 170,228           | 2,580,364         | 
+-------------------+-------------------+-------------------+ 
| Dr Stephen Wright | 177,970           | 1,495,150         | 
+-------------------+-------------------+-------------------+ 
 
The exercise price of the Awards is 0.1p per Share, the par value of the Shares. 
 
The Awards will ordinarily vest on 19 July 2013 subject to the following 
performance conditions having been achieved: 
 
One quarter of the award will vest upon achievement of regulatory approvals of 
the Company's lead product, Sativex , in a further 6 European countries 
(excluding UK and Spain) and 3 non-EU countries; 
 
One quarter of the award will vest upon the conclusion one new significant 
non-Sativex license agreement; 
 
One quarter of the award will vest upon the successful completion of a Phase II 
proof of concept clinical trial in one non-Sativex product; and 
 
One quarter of the award will vest if, on the vesting date, the GW 
Pharmaceutical plc share price has both increased and outperformed the FTSE AIM 
All share Index over the period from the date of grant until vesting of the 
option. 
 
Once vested, an Award may be exercised at any time prior to the tenth 
anniversary of the date of grant. 
 
 
For further information, please contact: 
 
GW Pharmaceuticals PLC                                                +44 
(0)1980 557 000 
Adam George, Company Secretary 
 
Piper Jaffray Ltd (Nominated Adviser) 
Neil Mackison/Rupert Winckler                                          +44  (0) 
203 142 8700 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSLLFVSDVIALII